Premium
The selective cyclooxygenase‐2 inhibitor SC‐236 reduces liver fibrosis by mechanisms involving non‐parenchymal cell apoptosis and PPARγ activation
Author(s) -
Planagumà Anna,
Clària Joan,
Miquel Rosa,
LópezParra Marta,
Titos Esther,
Masferrer Jaime L.,
Arroyo Vicente,
Rodé Joan
Publication year - 2005
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fj.04-2753fje
Subject(s) - hepatic stellate cell , peroxisome proliferator activated receptor , ccl4 , fibrosis , apoptosis , endocrinology , receptor , inflammation , prostaglandin d2 , hydroxyproline , medicine , hepatic fibrosis , chemistry , agonist , prostaglandin , rosiglitazone , kupffer cell , cancer research , biology , carbon tetrachloride , biochemistry , organic chemistry
The importance of inflammation in initiating the sequence of events that lead to liver fibrosis is increasingly recognized. In this study, we tested the effects of SC‐236, a selective cyclooxygenase (COX)‐2 inhibitor, in rats with carbon tetrachloride (CCl 4 )‐induced liver fibrosis. Livers from CCl 4 ‐treated rats showed increased COX‐2 expression and 15‐deoxy‐prostaglandin (PG)J 2 (15d‐PGJ 2 ) formation, as well as decreased peroxisome proliferator‐activated receptor (PPAR)γ expression. In these animals, SC‐236 reduced liver fibrosis as revealed by histological analysis and by a reduction in hepatic hydroxyproline levels, metalloproteinase‐2 activity, and α‐smooth muscle actin expression. Interestingly, SC‐236 normalized 15d‐PGJ 2 levels and restored PPARγ expression in the liver of CCl 4 ‐treated rats. In isolated hepatic stellate cells (HSCs)—the major player in liver fibrogenesis—and Kupffer cells—the cell type primarily responsible for increased hepatic COX‐2—SC‐236 exhibited remarkable pro‐apoptotic and growth inhibitory properties. Of interest, SC‐236 decreased HSC viability to a similar extent than the PPARγ ligand rosiglitazone. Moreover, SC‐236 significantly induced PPARγ expression in HSCs and acted as a potent PPARγ agonist in a luciferase‐reporter trans‐activation assay. These data indicate that, by mechanisms involving non‐parenchymal cell apoptosis and PPARγ activation, the selective COX‐2 inhibitor SC‐236 might have therapeutic potential for prevention of liver fibrosis.